Physician profile
Sara Scheu
NPI 1790376002
$4,545.72
in general payments reported to CMS, 2019-2025
26 companies · $1,711 in 2025
The $1,711 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $187 · 2022: $190 · 2023: $923 · 2024: $1,535 · 2025: $1,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,169.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,192.57 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $962.99 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $294.38 | 2024-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $292.71 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $224.74 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $193.34 | 2023-2025 | Entyvio, Gattex |
| Neuraxis, INC. | $144.10 | 2025 | |
| Madrigal Pharmaceuticals | $142.89 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $142.29 | 2023-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $119.37 | 2024-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $91.79 | 2024-2025 | Rebyota |
| Genzyme Corporation | $85.51 | 2023-2025 | |
| Ardelyx, INC. | $84.60 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $80.46 | 2024 | |
| Intercept Pharmaceuticals, INC. | $77.48 | 2023-2024 | Ocaliva |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $73.09 | 2023-2024 | Renflexis, Hadlima |
| Ironwood Pharmaceuticals, INC | $53.29 | 2023-2024 | Linzess |
| Braintree Laboratories, INC. | $50.69 | 2023-2024 | Suflave |
| Ipsen Biopharmaceuticals, INC | $50.33 | 2025 | Iqirvo, Bylvay |
| Fresenius Kabi USA, LLC | $47.61 | 2023 | Idacio |
| Nestle Healthcare Nutrition INC. | $36.70 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.64 | 2023-2024 | Cyltezo |
| Phathom Pharmaceuticals, INC. | $26.34 | 2025 | Voquezna |
| Boston Scientific Corporation | $23.25 | 2025 | Watchman Flx |
| Amgen INC. | $15.91 | 2022 | |
| Merck Sharp & Dohme LLC | $11.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Scheu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.